Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥200.00 - ¥518.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)162.19K
Market Cap
¥8.96B
Enterprise Value¥6.74K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding39,473,118
10 Day Avg. Volume177,350
30 Day Avg. Volume162,186
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageRelatively low leverage gives CellSeed more balance-sheet flexibility than a heavily indebted biotechnology company. This can reduce interest and refinancing pressure, preserve options for investment, and provide some capacity to manage funding needs while development activities continue.
Healthy Gross MarginA consistently healthy gross margin indicates that CellSeed’s offerings have generated positive gross profit before operating expenses. If revenue recovers, this underlying economics could provide a foundation for operating leverage, although the current cost base remains too large.
Regenerative Medicine FocusCellSeed operates in a specialized regenerative-medicine area with an integrated focus on therapies, cell-sheet engineering, and supporting technology. This concentrated platform may support longer-term commercialization opportunities as products and related services advance through development.
Bears Say
Sharp Revenue ContractionThe sharp 2025 revenue decline shows that recent commercial performance has deteriorated materially rather than following a stable growth trajectory. Persistently lower revenue would reduce the base available to absorb fixed operating costs and could delay progress toward sustainable profitability.
Severe Operating LossesVery large and widening losses indicate that CellSeed’s current operating cost base is far above the revenue scale it is producing. Unless revenue expands substantially or expenses are reduced, ongoing losses can erode equity and limit the company’s ability to fund development internally.
Persistent Cash BurnContinuous negative operating and free cash flow means the business has not demonstrated self-funding operations. Sustained cash consumption increases reliance on external financing, while declining equity raises the risk that future funding could further weaken shareholder value or flexibility.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥200.00 and its highest was ¥518.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥8.96B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 60 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Aug 13, 2026. The company reported -¥8.69 earnings per share for the quarter.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 39,473,118 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥8.69 in its last earnings report. Following the earnings report the stock price went down -0.433%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―